AbbVie/ABBV

$166.41

1.06%
-
1D1W1MYTD1YMAX

About AbbVie

AbbVie Inc. is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica, Venclexta/Venclyxto, Epkinly and Elahere; aesthetics products, which include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, which include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy and Qulipta; eye care products, which consists of Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis and Other eye care, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers.

Ticker

ABBV

Sector

Healthcare

Trading on

NYSE

Industry

Biotechnology & Drugs

CEO

Richard Gonzalez

Employees

50,000

Headquarters

North chicago, United States

AbbVie Metrics

BasicAdvanced
$294.65B
Market cap
61.19
P/E ratio
$2.72
EPS
0.59
Beta
$5.92
Dividend rate
3.73%
Dividend yield
$294.65B
0.58916
$182.89
$130.96
5.64M
$5.92
0.872
0.764
503.803
573.214
220.94%
149.348
9.12%
3.56%
34.9%
4.73%
61.193
5.425
28.366
25.571
3.98%
3.56%
3.73%
-6.44%
-58.98%
5.85%
-0.06%
7.84%

What the Analysts think about AbbVie

Analyst Ratings

Majority rating from 29 analysts.
Buy

Price Targets

Average projection from 24 analysts.
10.99% upside
High $207.00
Low $161.00
$166.41
Current price
$184.70
Average price target

AbbVie Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
5.74% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$14.3B
2.69%
Net income
$822M
-53.77%
Profit margin
5.74%
-55.02%

AbbVie Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 0.84%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$2.46
$2.91
$2.95
$2.79
-
Expected
$2.46
$2.81
$2.86
$2.77
$2.22
Surprise
0.11%
3.69%
3.25%
0.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for AbbVie stock?

AbbVie (ABBV) has a market cap of $294.65B as of April 22, 2024.

What is the P/E ratio for AbbVie stock?

The price to earnings (P/E) ratio for AbbVie (ABBV) stock is 61.19 as of April 22, 2024.

Does AbbVie stock pay dividends?

Yes, the AbbVie (ABBV) stock pays dividends to shareholders. As of April 22, 2024, the dividend rate is $5.92 and the yield is 3.73%. AbbVie has a payout ratio of 220.94% on a trailing twelve-month basis.

When is the next AbbVie dividend payment date?

The next AbbVie (ABBV) dividend payment is scheduled for May 15, 2024.

What is the beta indicator for AbbVie?

AbbVie (ABBV) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the AbbVie stock price target?

The target price for AbbVie (ABBV) stock is $184.7, which is 10.99% above the current price of $166.41. This is an average based on projections from 24 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell AbbVie stock

Buy or sell AbbVie stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing